Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03084536 | PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery | completed | Phase 2 | 134 | Washington University School of MedicineOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT00470704 | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | completed | Phase 2 | 87 | Nancy Lin, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT02993159 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | completed | Phase 2 | 100 | Northwestern UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT01889238 | Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | completed | Phase 2 | 118 | PfizerINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT06265077 | Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients | completed | Phase 1 / Phase 2 | 58 | Noha MansourOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03206203 | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | completed | Phase 2 | 106 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02491983 | Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer(PARSIFAL) | completed | Phase 2 | 486 | MedSIROTHER | 7 | Dec 9, 2024 | clinicaltrials |
| NCT02632045 | Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer(MAINTAIN) | completed | Phase 2 | 169 | Melissa K AccordinoOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | completed | Phase 1 / Phase 2 | 89 | Syndax PharmaceuticalsINDUSTRY | 2 | Dec 4, 2024 | clinicaltrials |
| NCT03487666 | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | completed | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04111510 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 6 | Yale UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03356860 | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.(B-IMMUNE) | completed | Phase 1 / Phase 2 | 57 | Grand Hôpital de CharleroiOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02339532 | Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status(NeoTOP) | completed | Phase 2 | 86 | UNICANCEROTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02229084 | Vaccination of High Risk Breast Cancer Patients | completed | Phase 1 / Phase 2 | 58 | University of ArkansasOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02938442 | Vaccination of Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 16 | University of ArkansasOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03227328 | CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO(KENDO) | completed | Phase 2 | 52 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT01827787 | Eribulin in HER2 Negative Metastatic BrCa | completed | Phase 2 | 83 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT00221221 | Physical Activity Promotion in Breast Cancer Survivors | completed | Phase 2 / Phase 3 | 300 | University of AlbertaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT02980341 | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 182 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Oct 30, 2024 | clinicaltrials |
| NCT06654570 | Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial | completed | Phase 2 | 20 | Helsinki University Central HospitalOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04307329 | Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial(MIMOSA) | completed | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03205761 | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer(COMETABreast) | completed | Phase 2 | 11 | Spanish Breast Cancer Research GroupOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT03004183 | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC(STOMP) | completed | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03164993 | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer(ALICE) | completed | Phase 2 | 68 | Oslo University HospitalOTHER | 2 | Oct 15, 2024 | clinicaltrials |
| NCT03409198 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer(ICON) | completed | Phase 2 | 82 | Oslo University HospitalOTHER | 2 | Oct 15, 2024 | clinicaltrials |
| NCT02187991 | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | completed | Phase 2 | 169 | US Oncology ResearchINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03839823 | Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer(RIGHT Choice) | completed | Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 13 | Oct 9, 2024 | clinicaltrials |
| NCT04664972 | Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC | completed | Phase 2 | 212 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT00626106 | QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 156 | NantCell, Inc.INDUSTRY | 9 | Sep 19, 2024 | clinicaltrials |
| NCT01074970 | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | completed | Phase 2 | 135 | Hoosier Cancer Research NetworkOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02453737 | A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca | completed | Phase 2 | 170 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02613416 | Denosumab and MRI Breast Imaging(Dmab) | completed | Phase 2 | 42 | Alison StopeckOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT05960201 | Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma | completed | Phase 2 | 23 | Asan Medical CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03530696 | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer(T-DM1) | completed | Phase 2 | 55 | University of ArizonaOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05021900 | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT05163106 | Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole(NEOLETRIB) | completed | Phase 2 | 85 | University Hospital, AkershusOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04464174 | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer(PATHFINDER) | completed | Phase 2 | 54 | MedSIROTHER | 2 | Jul 26, 2024 | clinicaltrials |
| NCT02053636 | A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer(FINESSE) | completed | Phase 2 | 76 | Institut de Recherches Internationales ServierOTHER | 9 | Jul 25, 2024 | clinicaltrials |
| NCT01471106 | Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | completed | Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02981303 | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | completed | Phase 2 | 64 | HiberCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | completed | Phase 2 | 406 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03395899 | Pre-operative Immunotherapy Combination Strategies in Breast Cancer(ECLIPSE) | completed | Phase 2 | 71 | Queen Mary University of LondonOTHER | 1 | Jun 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 24, 2024source: clinicaltrials